Medication Adjustment for Uncontrolled Type 2 Diabetes

Rationale for Sulfonylurea Use

• The American Diabetes Association recommends sulfonylureas as a second-line treatment for uncontrolled type 2 diabetes due to their greater glucose-lowering efficacy, with a reduction in HbA1c of approximately 1.5 percentage points 3
• Patients with uncontrolled type 2 diabetes can be effectively treated with sulfonylureas when metformin alone is insufficient, with evidence supporting their use in this population 2, 4, 5

Sulfonylurea Selection and Dosing

• The American College of Clinical Endocrinologists recommends choosing gliclazide or glipizide over glibenclamide to minimize hypoglycemia risk, with gliclazide having a lower risk of hypoglycemia 3
• The initial dose of gliclazide MR should be 30mg once daily with breakfast, with the option to increase to a maximum of 120mg daily as needed 3

Monitoring and Safety Considerations

• The American Diabetes Association recommends monitoring fasting glucose weekly initially, then monthly once stable, and checking HbA1c every 3 months to assess long-term control 1
• Renal function should be monitored, with metformin dose reduction or discontinuation if eGFR falls below 45 mL/min/1.73m² or 30 mL/min/1.73m², respectively 6, 7

Treatment Goals and Intensification

• The American Association of Clinical Endocrinologists recommends an HbA1c goal of <8% for patients with cardiovascular disease, with a target fasting glucose of <180 mg/dL and postprandial glucose of 140-180 mg/dL 1
• If HbA1c remains >8% despite maximum tolerated sulfonylurea dose, consider insulin therapy as the next step, with basal insulin (NPH or long-acting) as an option to add to the metformin-sulfonylurea combination 1, 2, 8